SUPN supply chain intelligence for Supernus Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Supernus Pharmaceuticals, Inc. (SUPN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BRITANNIA | BRITANNIA | 92% | Per the Agreement, Britannia has an obligation to supply us with APOKYN for our marketing and sale of the product. |
| NAVITOR-PHARMACEUTICALS-INC | NAVITOR-PHARMACEUTICALS-INC | 92% | Supernus Pharmaceuticals, Inc. entered into an Asset Purchase Agreement with Navitor Pharmaceuticals, Inc., a Delaware corporation, under which the Company agreed to acquire from the Sellers all of t… |
| NAVITOR-PHARMACEUTICALS-LLC | NAVITOR-PHARMACEUTICALS-LLC | 92% | Supernus Pharmaceuticals, Inc. entered into an Asset Purchase Agreement with Navitor Pharmaceuticals, LLC, a Delaware limited liability company, together with related ancillary transaction documents,… |
| ZAMBON | ZAMBON | 92% | Under the Supply Agreement, we must purchase from Zambon and Zambon must provide to us all XADAGO finished products for the U.S. market. |
| APHENA-PHARMA-SOLUTIONS | APHENA-PHARMA-SOLUTIONS | 85% | For Qelbree, Trokendi XR, GOCOVRI, and Oxtellar XR we currently rely on third-party CMOs for the manufacturing and packaging of final commercial products. |
| CATALENT-PHARMA-SOLUTIONS | CATALENT-PHARMA-SOLUTIONS | 85% | For Qelbree, Trokendi XR, GOCOVRI, and Oxtellar XR we currently rely on third-party CMOs for the manufacturing and packaging of final commercial products. |
| PACKAGING-COORDINATORS-INC | PACKAGING-COORDINATORS-INC | 85% | For Qelbree, Trokendi XR, GOCOVRI, and Oxtellar XR we currently rely on third-party CMOs for the manufacturing and packaging of final commercial products. |
| PATHEON-PHARMACEUTICALS-INC | PATHEON-PHARMACEUTICALS-INC | 85% | For Qelbree, Trokendi XR, GOCOVRI, and Oxtellar XR we currently rely on third-party CMOs for the manufacturing and packaging of final commercial products. |
| BIIB | Biogen Inc. | 72% | Reciprocal relationship from BIIB graph: Nephropathy PNH Paroxysmal Nocturnal Hemoglobinuria PPACA Patient Protection and Affordable Care Act PPD Postpartum Depression PPMS Primary Progressive MS PRV… |
| CAH | Cardinal Health, Inc. | 72% | Reciprocal relationship from CAH graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from CAH graph: Reciprocal relationship from SUPN graph: could be harmed. The majority of our … |
| CAH | Cardinal Health, Inc. | 72% | could be harmed. The majority of our product sales are to pharmaceutical wholesalers, specialty pharmacies, and distributors who, in turn, sell our products to pharmacies, hospitals, and other custom… |
| COLL | Collegium Pharmaceutical, Inc. | 72% | Reciprocal relationship from COLL graph: . At the same time, the Trump Administration has 61 Table of Contents endorsed a federal moratorium on the enforcement of state AI laws, including through a D… |
| MCK | McKesson Corporation | 72% | could be harmed. The majority of our product sales are to pharmaceutical wholesalers, specialty pharmacies, and distributors who, in turn, sell our products to pharmacies, hospitals, and other custom… |
| MCK | McKesson Corporation | 72% | Reciprocal relationship from MCK graph: Reciprocal relationship from SUPN graph: could be harmed. The majority of our product sales are to pharmaceutical wholesalers, specialty pharmacies, and distri… |
| ORANY | ORANY | 72% | y to it, then the Company may be subject to penalties, both civil and criminal, damages, fines, exclusion from federal healthcare programs, and/or the curtailment or restructuring of its operations. … |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from ORAN… |
| SGIOF | Shionogi & Co., Ltd. | 72% | Reciprocal relationship from SGIOF graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from SGIOF graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from SGIO… |
| SGIOF | Shionogi & Co., Ltd. | 72% | following promises in the Biogen Collaboration Agreement that were evaluated under the scope of ASC 606: delivery of (i) a co-exclusive license for SAGE-217 products in the U.S.; (ii) an exclusive li… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | Reciprocal relationship from TKPHF graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from SUPN graph: cidental contamination or injury … |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | cidental contamination or injury from these materials. In the event of an accident, local, city, state, or federal authorities may curtail the use of these materials and may interrupt our business op… |
| TMO | Thermo Fisher Scientific Inc. | 72% | Reciprocal relationship from TMO graph: Reciprocal relationship from SUPN graph: hat used in Phase 2 clinical trials, nor do we have plans to develop our own manufacturing operations in the foreseeab… |
| TMO | Thermo Fisher Scientific Inc. | 72% | hat used in Phase 2 clinical trials, nor do we have plans to develop our own manufacturing operations in the foreseeable future to support Phase 3 clinical trials or commercial production. We current… |
| ZVRA | Zevra Therapeutics, Inc. | 72% | Reciprocal relationship from ZVRA graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from ZVRA graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from ZVRA g… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BIOGEN | BIOGEN | 92% | The Company has a collaboration agreement with Biogen (Biogen Collaboration Agreement) for the co-commercialization of ZURZUVAE in the U.S. |
| CAH | Cardinal Health, Inc. | 72% | Reciprocal relationship from CAH graph: Reciprocal relationship from SUPN graph: could be harmed. The majority of our product sales are to pharmaceutical wholesalers, specialty pharmacies, and distri… |
| CAH | Cardinal Health, Inc. | 72% | could be harmed. The majority of our product sales are to pharmaceutical wholesalers, specialty pharmacies, and distributors who, in turn, sell our products to pharmacies, hospitals, and other custom… |
| MCK | McKesson Corporation | 72% | could be harmed. The majority of our product sales are to pharmaceutical wholesalers, specialty pharmacies, and distributors who, in turn, sell our products to pharmacies, hospitals, and other custom… |
| MCK | McKesson Corporation | 72% | Reciprocal relationship from MCK graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from MCK graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from MCK grap… |
| RAPP | Rapport Therapeutics, Inc. | 72% | Reciprocal relationship from RAPP graph: into longer-term commercial supply agreements to fulfill and secure our production needs. While the drug substances used in our product candidates are manufac… |
| SGIOF | Shionogi & Co., Ltd. | 72% | . • Shionogi - The Company also has a collaboration agreement with Shionogi & Co., Ltd. (Shionogi) (Shionogi Collaboration Agreement) whereby the Company is entitled to receive royalties and mileston… |
| SGIOF | Shionogi & Co., Ltd. | 72% | Reciprocal relationship from SGIOF graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from SGIOF graph: Reciprocal relationship from SUPN graph: . • Shionogi - The Company also h… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | Reciprocal relationship from TKPHF graph: Reciprocal relationship from SUPN graph: cidental contamination or injury from these materials. In the event of an accident, local, city, state, or federal a… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | cidental contamination or injury from these materials. In the event of an accident, local, city, state, or federal authorities may curtail the use of these materials and may interrupt our business op… |
| TMO | Thermo Fisher Scientific Inc. | 72% | Reciprocal relationship from TMO graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from TMO graph: Reciprocal relationship from SUPN graph: d other specialized health care provi… |
| TMO | Thermo Fisher Scientific Inc. | 72% | d other specialized health care providers in the U.S. in the Parkinson's area. Another sales force focuses on psychiatrists, pediatricians, primary care physicians, and advanced practice providers in… |
| UTHR | United Therapeutics Corporation | 72% | .e., at the time of sale to wholesalers/distributors). This liability is recorded as a reduction to gross product sales, and an increase in Accrued product returns and rebates. The liability is recor… |
| UTHR | United Therapeutics Corporation | 72% | Reciprocal relationship from UTHR graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from UTHR graph: Reciprocal relationship from SUPN graph: .e., at the time of sale to wholesa… |
| XENE | Xenon Pharmaceuticals Inc. | 72% | Reciprocal relationship from XENE graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from XENE graph: velopment and marketing efforts of our collaborators. • Our reliance on thir… |
| ZVRA | Zevra Therapeutics, Inc. | 72% | Reciprocal relationship from ZVRA graph: eparation. UCDs are a group of rare genetic disorders that can cause harmful ammonia to build up in the blood, potentially resulting in brain damage and neuro… |
| ACORDA-THERAPEUTICS-INC | ACORDA-THERAPEUTICS-INC | 62% | f our major products were to become subject to problems, such as changes in prescription growth rates, unexpected side effects, loss of intellectual property protection, supply chain or product suppl… |
| CENCORA-INC-CARDINAL-HEALTH-INC | CENCORA-INC-CARDINAL-HEALTH-INC | 62% | ounts, our business could be harmed. The majority of our product sales are to pharmaceutical wholesalers, specialty pharmacies, and distributors who, in turn, sell our products to pharmacies, hospita… |
| CO-LTD | CO-LTD | 62% | rmation from other sources, including public and proprietary sources; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially fr… |
| ELAN-PHARMACEUTICALS-LLC | ELAN-PHARMACEUTICALS-LLC | 62% | ear term of the agreement is subject to automatic renewal periods unless canceled by either party. Either party may terminate the agreement under certain circumstances, including a material breach of… |
| MERZ-PHARMACEUTICALS-LLC | MERZ-PHARMACEUTICALS-LLC | 62% | f our major products were to become subject to problems, such as changes in prescription growth rates, unexpected side effects, loss of intellectual property protection, supply chain or product suppl… |
| MERZ-PHARMA-GMBH | MERZ-PHARMA-GMBH | 62% | ear term of the agreement is subject to automatic renewal periods unless canceled by either party. Either party may terminate the agreement under certain circumstances, including a material breach of… |
| NAVITOR-PHARMACEUTICALS-INC | NAVITOR-PHARMACEUTICALS-INC | 62% | of discontinuance to withdraw Osmolex ER from distribution. Distribution of Osmolex ER ceased on April 1, 2024. The Company recognized noncash royalty revenues of $ 4.0 million, and $ 9.8 million for… |
| NAVITOR-PHARMACEUTICS-LLC | NAVITOR-PHARMACEUTICS-LLC | 62% | red to purchase a minimum quantity of finished products on an annual basis. This minimum purchase requirement represents the in-substance fixed contract consideration associated with the dedicated ma… |
| PATHEON-PHARMACEUTICALS-INC | PATHEON-PHARMACEUTICALS-INC | 62% | the U.S. are effectively targeting healthcare providers to support and grow our key commercial products. One sales force focuses on serving movement disorder specialists and other specialized health … |
| SAGE-THERAPEUTICS-INC | SAGE-THERAPEUTICS-INC | 62% | ised of the following (dollars in thousands): Three Months Ended March 31, Change 2026 2025 Amount Net cash provided by (used in): Operating activities $ 66,524 $ 30,599 $ 35,925 Investing activities… |
| STADA-ARZNEIMITTEL-AG | STADA-ARZNEIMITTEL-AG | 62% | the U.S. are effectively targeting healthcare providers to support and grow our key commercial products. One sales force focuses on serving movement disorder specialists and other specialized health … |
| SUNOVION-PHARMACEUTICALS-INC | SUNOVION-PHARMACEUTICALS-INC | 62% | f our major products were to become subject to problems, such as changes in prescription growth rates, unexpected side effects, loss of intellectual property protection, supply chain or product suppl… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| SUPN-DEBT-12822 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2022-12-31. |
| SUPN-DEBT | Debt stack $401.4M | 90% | Market cache reports total debt of $401.4M. |
| SUPN-DEBT-12821 | Warrants outstanding: 80.91 | 90% | xbrl warrant detail from xbrl 2023-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| SUPN-OWNER-BLACKROCK-INC | BlackRock, Inc. | 90% | 13F overlay lists BlackRock, Inc. as top holder; 331 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| HLNCF | Haleon plc | 100.00 | 2 | |
| HLN | Haleon plc | 100.00 | 2 | |
| CAH | Cardinal Health, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CLLS | Cellectis S.A. | 100.00 | 2 | |
| ICLR | ICON Public Limited Company | 100.00 | 2 | |
| GRDN | Guardian Pharmacy Services, Inc. | 100.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 | |
| BIIB | Biogen Inc. | 100.00 | 1 | ['supplier'] |
| ARDX | Ardelyx, Inc. | 100.00 | 2 | |
| BHPLF | BHP Group Limited | 100.00 | 2 | |
| BTAI | BioXcel Therapeutics, Inc. | 100.00 | 2 | |
| GILD | Gilead Sciences, Inc. | 100.00 | 2 | |
| CVS | CVS Health Corporation | 100.00 | 2 | |
| HALO | Halozyme Therapeutics, Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| ORANY | ORANGE | 100.00 | 1 | ['supplier'] |
| CLH | Clean Harbors, Inc. | 100.00 | 2 | |
| IDXG | Interpace Biosciences, Inc. | 100.00 | 2 |